These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659 [TBL] [Abstract][Full Text] [Related]
26. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420 [TBL] [Abstract][Full Text] [Related]
27. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454 [TBL] [Abstract][Full Text] [Related]
28. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940 [TBL] [Abstract][Full Text] [Related]
29. FDG PET in the management of lymphoma: a clinical perspective. Hoskin PJ Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880 [No Abstract] [Full Text] [Related]
30. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335 [TBL] [Abstract][Full Text] [Related]
32. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671 [TBL] [Abstract][Full Text] [Related]
33. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408 [TBL] [Abstract][Full Text] [Related]
34. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma. Araf S; Montoto S Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301 [TBL] [Abstract][Full Text] [Related]
35. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514 [TBL] [Abstract][Full Text] [Related]
36. The role of PET imaging in lymphoma. Burton C; Ell P; Linch D Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980 [TBL] [Abstract][Full Text] [Related]
37. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836 [TBL] [Abstract][Full Text] [Related]
38. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]. Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735 [TBL] [Abstract][Full Text] [Related]
39. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Kumar R; Maillard I; Schuster SJ; Alavi A Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559 [TBL] [Abstract][Full Text] [Related]
40. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Partridge S; Timothy A; O'Doherty MJ; Hain SF; Rankin S; Mikhaeel G Ann Oncol; 2000 Oct; 11(10):1273-9. PubMed ID: 11106116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]